Table 2C.
Baseline clinical characteristics in patients who were in the studies that investigated the association between LVH and the recurrence of AF after catheter ablation.
| References | Study type | Criteria of LVH | Groups | n | Age (years) | Male (%) | Paroxysmal AF (%) | Follow-Up |
|---|---|---|---|---|---|---|---|---|
| Akkaya et al. (23) | Retrospective cohort study | LVMI > 104 g/m2 (women)Or >116 g/m2 (men) | LVH | 111 | 65.4 ± 11.3 | 95 (77.9) | 49.90% | 11.1 ± 3.8 months |
| NO LVH | 246 | 64.8 ± 12.3 | 165 (58.5) | |||||
| Li et al. (24) | Prospective cohort study | Romhilt-Estes point score≥5 points | LVH | 207 | 61.6 ± 10.8 | 144 (66.1) | 100% | 42 months |
| NO LVH | 213 | 60.2 ± 9.8 | 141 (64.7) |
LVH, left ventricular hypertrophy; LVMI, left ventricular mass index.